Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons
| Autor: | Richard M. Novak, M. van den Berg-Wolf, C. Henley, Teresa Yurik, Grace Peng, Michael J. Kozal, Rodger D. MacArthur, Barry Schmetter, L. Besch, Marjorie Dehlinger, Li Chen |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Anti-HIV Agents HIV Infections Pharmacology Gastroenterology immune system diseases Abacavir Internal medicine parasitic diseases medicine Clinical endpoint Humans Pharmacology (medical) Didanosine Reverse-transcriptase inhibitor business.industry Stavudine Hazard ratio virus diseases Lamivudine HIV Protease Inhibitors Dideoxynucleosides CD4 Lymphocyte Count Infectious Diseases Treatment Outcome Tolerability HIV-1 Reverse Transcriptase Inhibitors Drug Therapy Combination business medicine.drug |
| Zdroj: | HIV clinical trials. 5(6) |
| ISSN: | 1528-4336 |
| Popis: | Purpose: The combination of abacavir + lamivudine (ABC+3TC) versus didanosine + stavudine (ddI+d4T), each combined with other classes of antiretrovirals (ARVs) in ARV-naive patients, was compared for the combined endpoint of time to plasma HIV RNA >50 copies/mL (at or after the 8-month visit) or death (primary endpoint) in a nested substudy of an ongoing multicenter randomized trial. Method: The substudy enrolled 182 patients; mean HIV RNA and CD4+ cell counts at baseline were 5.1 log10 copies/mL and 212 cells/mm3, respectively. Results: After a median follow-up of 28 months, rates of primary endpoint were 57.2 and 67.8 per 100 person-years for the ABC+3TC and ddI+d4T groups (hazard ratio [HR] = 0.81, 95% confidence interval [CI] 0.58-1.14, p = .23). Conclusion: There was a trend for treatments containing ABC+3TC to be better than treatments containing ddI+d4T with respect to HIV RNA decreases, CD4+ cell count increases, and tolerability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|